ARTICLE | Company News
Cubist other research news
May 28, 1996 7:00 AM UTC
Cubist received two Phase II SBIRs totaling $1.3 million from the National Institutes of Allergy and Infectious Diseases to identify small molecule compounds against the two pathogens. ...